Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Here's what Analyt Group has to say about Internet Bashing:
Weekly Thoughts: "Bashing" Business is Booming (Part II)
Who bashers prey upon? Consider the elderly that are investing for
retirement, they find their way to the message boards for validation only
to see false posts about "SEC Violations" and "Class action suits"... or
the head of a "typical growing family", with children to put through
college, who is monitoring a message board only to read posts by a "pack
of 15 to 20 Bashers" (probably 5 or 6 under various alias's) posting
continuous disinformation... what do you think these new investors will
do? It's safer to not buy or even sell the stock, put the money back in
the bank than to deal with all this wind of "unsupported" negative stuff.
There are some rules you may want to consider to avoid making any
emotional decision on an stock investment
Rule 1: Remember, BASHERS NEVER Bash A BAD STOCK.
Check the boards for stocks with no potential. There are never any
bashers. Because those who hire bashers know a bad stock is always bad.
Further bashing will create more audience in the investment community.
Bashers only go after stocks that are moving up or have excellent
potential to do so. Bashers work to bring the price down to either
increase their position at the expense of others or help a short make
their bones.
Rule 2: BASHERS ALWAYS BRING UP OLD NEWS THAT YOU HAVE HEARD MANY TIMES.
Any startup companies always have a few bits of bad news. The basher will
post this over and over again. Unsophisticated Bashers will try to freshen
up old news with a new date or by-line in an attempt to fool you.
Rule 3: BASHERS POST MANY TIMES A DAY.
They try to wear you out. They comment on everything, every other post,
and can answer every question. THEY KNOW IT ALL! There is no positive
comment they won't bash. They try to control the board. True longs may
have to confront bashers or they will appear to newbies as being the
people with all the information. This is best accomplished by posting
positive, well researched data on the company, repetitively, while trying
hard not to engage bashers in direct repartee. This is how basher earns
their bonus.
Rule 4: BASHERS WILL LIE TO YOUR FACE.
Never trust a basher. This is a very important note. The truth on startup
companies is that they make mistakes. Which startup hasn't? The basher
will compare your issue to another company, financials - deals -
management, etc., trying to lure you into making an Apples to Oranges
comparison. Remember each company is unique and while it is prudent to
seek out established indicators, do so with care and don't take someone
else's word for it. Strive to come up with at least a "six-pack" of
indicators so your vision of the state of a company is not tied to a
single barometer. Not doing so is tantamount to going to a Race Track and
betting on the "Pretty Brown Horsey".
BASHERS WANT TO WHISPER IN YOUR EAR - PLANT A SEED OF DOUBT, AND HOPE THAT
YOU ARE NOT SAVVY ENOUGH TO RESEARCH THE TRUTH ON YOUR OWN.
This is your investment... work for it, protect it and don't panic on the
words of very shadowy figure that "has your best interest in their heart".
Consider that one factor: Someone you have never met, is not a member of
your family, is now, out of the goodness of their hearts - GIVING YOU FREE
ADVICE (that you didn't ask for). It's a no brainer. They have motives.
Something would have to be mentally wrong, albeit it is true in this case,
with someone to continue to waste valuable time posting negative comment
after negative comment about any company. They have some sort of stake,
and if not we challenge them to come up with a better reason why they're
here. They don't have one except monetary reasons. If the SEC were to open
the files on their accounts we are sure some interesting woo would creep
out.
Rule 5: Bashers know YOU CAN'T VERIFY THEIR STATEMENTS
Ask them to give you a viable link to this information and phone numbers
to further your DD. That's why they make the vague statements they do.
They rely on you being lazy to research their droppings other than to scan
the board for others opinions. This is particularly dangerous when you
consider that bashers work in packs and often validate and back up each
other nonsense with what appears to be "innocuous and unsolicited"
verification by comrade Bashers. Let's face it, we are all conditioned to
"believe" everything we see in writing. If others by virtue of their
"posts" also confirm this belief, then we are subconsciously doomed to
swallow the hook, line and sinker...
Rule 6: Bashers PLAY ON YOUR LACK OF KNOWLEDGE.
They can lie about information and you won't know the difference (unless
you have done your own DD on the company and know the truth and facts).
Rule 7: Bashers play on your lack of patience.
You have held a stock for a while. You knew it will be a big stock
someday, but the BASHER CAN GET TO YOU BECAUSE YOU ARE TIRED OF WAITING
FOR YOUR GAIN. That's when the Basher is best. You are tired. You have
forgotten the goal for the stock was to hold it for one year. The Basher
is bothersome, so you dump it on a bad day. Some others also dump. Then
you get mad for your loss and return to let everyone know how mad you are.
Then you turn into a semi-Basher as well. THE BASHER HAS WON, AND GAINED A
NEW ALLY - YOU!
Rule 8: BRING THE PRICE DOWN.
That is basher's job. The truth is not important. Lies are normal. Post
continuously on the board every day. They are trying to scare the newbies
that are just investigating a stock. They are trying to wear down the
faithful longs on the board and gain free reign and control.
Analytical Spectral Devices, Inc. and CDEX announce settlement agreement
Boulder, Colo., September 29 , 2006 — CDEX Inc. and Analytical Spectral Devices, Inc. announced today that they entered into a settlement agreement with regards to Civil Action No. 06-CV-426-RDB-CBS that was pending before the U.S. Federal District Court in Denver, Colorado. As part of the Settlement Agreement, CDEX has been fully licensed under ASD’s patent for liquid pharmaceuticals. CDEX acknowledges the validity of ASD’s patent and such acknowledgement shall continue for as long as the license remains in effect. In consideration of the settlement agreement, both parties have agreed to dismiss their respective claims against each other. The terms and conditions of the settlement agreement are otherwise confidential.
http://asdi.com/news-pr_CDEX%20lawsuit%20settlement_9-29-06.asp
U.S. Federal District Court Dismisses ASD and CDEX Lawsuits with Prejudice
ROCKVILLE, Md., Oct 03, 2006 (BUSINESS WIRE) -- CDEX Inc. (OTCBB: CEXI)
announced today that the U.S. Federal District Court in Denver, Colorado has
reviewed and approved the Stipulation to Dismiss that was filed in the Court on
September 29, 2006 as part of a settlement agreement reached between ASD and
CDEX with regards to Civil Action No. 06-CV-426-RDB-CBS. Today, the Court
entered an Order of Dismissal with Prejudice and vacated all pending actions
before the Court.
This action by the Court brings to a final end the patent infringement lawsuit
that was filed by ASD against CDEX. It also brings to a final close CDEX's
counterclaims of invalidity and unenforceability that the company filed in
response to ASD's lawsuit.
"This case was settled in a manner that was fair and equitable to both parties,
while preserving the company's rights and protecting the interests of our
shareholders," said Jim Griffin, CDEX President and CEO.
About CDEX Inc.
CDEX Inc. is a chemical detection technology development company that uses its
expertise to develop and market life safety/public safety products for the
healthcare, homeland security, and brand protection markets. CDEX's ValiMed
Medication Validation System is used for quality assurance to ensure that
high-risk medications that are compounded in hospital pharmacies are the correct
medication, in the correct concentration, and correct diluent before they are
administered to patients. CDEX technology can be used in homeland security
market applications to identify suspicious substances such as trace amounts of
explosives, in liquid or solid form, and illegal drugs for law enforcement in
the homeland security market. CDEX is headquartered in Rockville, Maryland with
its research and development laboratory, engineering, and manufacturing
operations in Tucson, Arizona. For more information, visit www.cdex-inc.com.
Any statements made in this press release which contain information that is not
historical are essentially forward-looking. Many forward-looking statements can
be identified by the use of words such as "expects," "plans," "may,"
"anticipates," "believes," "should," "intends," "estimates," and other words of
similar meaning. These statements are subject to risks and uncertainties that
cannot be predicted or quantified and, consequently, actual results may differ
materially from those expressed or implied by such forward-looking statements.
Such risks are detailed from time-to-time in filings with the Securities and
Exchange Commission. There is no obligation to publicly update any
forward-looking statements.
SOURCE: CDEX, Inc.
CDEX Quarterly Report September 13, 2006.
http://www.sec.gov/Archives/edgar/data/1173738/000121465906001841/0001214659-06-001841.txt
New ValiMed(TM) Medication Validation System DemonstratesUSP < 797 > Compliance at ASHP Summer Meeting Baxa Corporation demonstrates the next-generation ValiMed System for medication safety at booth no. 729 at the American Society of Health-System Ph
ENGLEWOOD, Colo., June 26, 2006 /PRNewswire via COMTEX/ -- Baxa Corporation
announces the release of the next-generation ValiMed Medication Validation
System at the summer meeting of the American Society for Health-System
Pharmacists. The ValiMed System validates medications and concentrations;
allowing users to detect counterfeit products for brand protection, provide
quality assurance for compounded products, and detect narcotic loss. The ValiMed
System ensures patient safety in real time, by verifying that medications are
correctly compounded.
ValiMed features patent-pending technology that validates in seconds the
strength of compounded doses of high risk medications prior to dispensing.
Verification of compounding accuracy and sterilization is a requirement under
USP 27-NF 22 Chapter < 797 >, which regulates the compounding of sterile
products. The ValiMed System can play a key role in demonstrating the safety of
compounded sterile products (CSPs) under these requirements.
The updated version of the ValiMed System -- shown for the first time at the
ASHP meeting -- incorporates reports used to comply with USP 797 requirements.
It also features a modified disposable, requiring a reduced sample volume for
testing. "This next-generation ValiMed System addresses customer requests,"
notes Product Manager Mark Thrasher. "It's more robust and the smaller sample
requirement more easily accommodates current pharmacy work flows."
During the meeting, Baxa representatives will demonstrate the ValiMed System's
capabilities in their booth, number 729. Pharmacists will see first-hand how the
system ensures the accuracy of their compounded solutions and helps them meet
both USP 797 verification and JCAHO requirements for patient safety.
About Baxa Corporation
Baxa, a customer-focused medical device company, provides innovative,
solution-based technologies for fluid handling and delivery. Its systems and
devices promote the safe and efficient preparation, handling, packaging, and
administration of fluid medications. Privately held, Baxa Corporation has
subsidiaries and sales offices in Canada and the United Kingdom; direct
representation in Belgium, Denmark, Finland, France, Germany, Luxembourg and The
Netherlands; and distribution partners worldwide. Further information is
available at www.baxa.com.
About CDEX, Inc.
CDEX Inc. (OTC Bulletin Board: CEXI), the manufacturer of the ValiMed System, is
a technology development company focused on producing equipment that uses using
chemical detection and validation technologies. CDEX technology is focused
currently on two distinct areas: (i) identification of substances of concern
(e.g., explosives and illegal drugs); and (ii) validation of substances for
anti-counterfeiting, brand protection and quality assurance. CDEX is
headquartered in Rockville, Maryland, with a primary research and development
laboratory in Tucson, Arizona. For more information, visit www.cdex-inc.com and
www.valimed.com.
CDEX Second Quarter Revenue Highest in Company's History; ValiMed Leads the Way
ROCKVILLE, Md., Jun 16, 2006 (BUSINESS WIRE) -- CDEX, Inc. (OTCBB:CEXI.OB)
announced today that it recorded the highest quarterly revenue in the history of
the company in the fiscal second quarter, ending April 30, 2006. Revenue was
$351,038 as compared to $23,860 during the second fiscal quarter of 2005. The
increase of $327,177 (or 1,371%) resulted from the delivery of ValiMed (TM)
medication verification systems to Baxa Corporation. Baxa represents the CDEX
ValiMed product line, exclusively in the USA and Canada.
During the period from January 2006 through April 2006, CDEX successfully
managed its production plan for the ValiMed medication verification system, that
included, but was not limited to the following: completing the ValiMed design
package; developing a new proprietary cuvette; identifying, qualifying, and
setting up contract manufacturers for ValiMed and the new proprietary cuvette;
developing new medications and drugs signatures for the ValiMed production
units, completing product certification testing and obtaining the TUV mark, and
delivering the first production units to Baxa on-time and on-budget.
"The shareholders, management, and staff of CDEX take great pride in what has
been accomplished. This achievement represents the culmination of several years
of research and development, determination, and perseverance by a lot of very
dedicated people to bring ValiMed to market. We are proud of what we have
achieved, and awed by the opportunities that are before us. The introduction of
ValiMed into the hospital pharmacy market is a significant contribution to
society. The ValiMed medication verification system gives clinicians and
healthcare professionals a quick, cost effective, and simple tool to further
ensure medication safety by verifying that medications are correctly compounded.
ValiMed can make a difference to hospital patients by preventing injuries and
the loss of life due to medication errors," said Jim Griffin, President and CEO
of CDEX, Inc.
About CDEX Inc.
CDEX Inc. is a technology development company with a current focus on developing
and marketing products using chemical detection and validation technologies. At
present, CDEX is devoting its resources to two distinct areas: (i) and quality
assurance (e.g., validation of prescription medication and detection of
counterfeit or sub-par products for brand protection). ValiMed is one line of
CDEX products for the healthcare market; and (ii) identification of substances
of concern (e.g., illegal drugs for law enforcement in the homeland security
market) CDEX is headquartered in Rockville, Maryland with its research and
development laboratory in Tucson, Arizona. For more information, visit
www.cdex-inc.com.
Any statements made in this press release which contain information that is not
historical are essentially forward-looking. Many forward-looking statements can
be identified by the use of words such as "expects," "plans," "may,"
"anticipates," "believes," "should," "intends," "estimates," and other words of
similar meaning. These statements are subject to risks and uncertainties that
cannot be predicted or quantified and, consequently, actual results may differ
materially from those expressed or implied by such forward-looking statements.
Such risks are detailed from time-to-time in filings with the Securities and
Exchange Commission. There is no obligation to publicly update any
forward-looking statements.
SOURCE: CDEX, Inc.
CONTACT: CDEX, Inc.
Jerry Blair, 301-881-0080
jblair@cdex-inc.com
Fourth Affirmative Defense In-Equitable Conduct.
(Thank You Pookie)
The 369 patent is un-enforceable as a result of inequitable conduct arising from plaintiffs and or plaintiffs councils intentional failure to disclose relevant prior art that was material to the patentability of the claims of the 369 patent.
Plaintiff was specifically aware of prior art including prior invention material to the patentability of the claims of the 369 patent before and during prosecution of the 369 patent.
Nevertheless upon information and belief plaintiff intentionally failed to disclose such material prior art to the us patent and trademark office USPTO thereby committing fraud on the uspto.
More specifically one of the inventors of the 369 patent Mr. Brian Curtis attended and FDA advisory board meeting for the process of Analytical Technologies subcommittee of the Advisory Committee for the Pharmaceutical Science held February 25 and 26 Curtis
Mr. Curtiss was an official industry guest participant of the FDA Advisory Committee for Pharmaceutical Science and was designated as a member of the Process Analytical Technology (PAT) Subcommittee working Group.
In such capacity he received testimony on Near Infra red NIR applications in pharmacy practice.
During the meetings among others things Pfizer Cooperation made a presentation entitled and industry perspective on the potential for "Emerging Process Analytical Technologies"
The presentation among other things included a detailed discussion of the use of NIR or pharmaceutical compounds.
In particular one of the presentation slides was entitled NIR Tablet Transmission Device.
This slide illustrated how the composition of a tablet may be analyzed using a NIR spectrum
Another presentation entitled Total Quality Management System (TQMS) was presented by AstraZeneca during the February 26 and 26 meetings.
The presentation also included a detailed discussion of the use of NIR analysis of pharmaceutical compounds.
Slides of this presentation show among other things a TQMS analyzer capable of analyzing tablets.
Plaintiff plaintiffs councils and Mr.,. Curtis all failed to disclosed the existence of this Prior Art which is material to the patentability of the claims of the 369 patent to the USPTO during prosecution of the 369 patent. In fact shortly after the FDA Advisory Board Meeting, Plaintiff rushed to the USPTO to file its alleged "own" patent application ) (The application for the 369 Patent) and did not inform the USPTO of for example, the Pfizer and the Astra Zeneca presentations.
Moreover, Upon information and belief no Pfizer or Astra Zeneca presentations upon information and Believe no Pfizer or Astra Zeneca individuals were named as inventors on the 369 patent. To the extent that incorrect inventors have been identified with the intent to deceiver the USPTO such would constitute fraud by Plaintiff on the USPTO...
ValiMed Receives Clean Bill of Health from TUV Rheinland of North America, Inc.
Monday April 10, 11:22 am ET
CDEX is Authorized to use TUV Mark on ValiMed
ROCKVILLE, Md.--(BUSINESS WIRE)--April 10, 2006--CDEX, Inc. (CEXI.OB) announced today that it received permission from TUV Rheinland of North America Inc. (www.us.tuv.com) to apply the TUV mark to the ValiMed(TM) 1.0 system after completing an exhaustive three month product certification testing and quality assurance inspection of the manufacturing processes. The ValiMed medication verification system, which was developed by CDEX (www.cdex-inc.com) and is exclusively distributed by Baxa (www.baxa.com), gives clinicians a quick, cost effective, and simple tool to further ensure medication safety by verifying that medications are correctly compounded.
More here...
http://biz.yahoo.com/bw/060410/20060410005699.html?.v=1
Cdex recently received a notification of allowance from the U.S. Patent and Trademark Office for a product that will detect explosives or controlled substances. Officials expect that patent to be issued this spring; Cdex has four additional patents pending in the United States, plus more internationally.
Colorado firm accuses Rockville’s Cdex of patent infringement
Experian.http://www.gazette.net/stories/040706/businew184605_31950.shtml
Friday, April 7, 2006
A Rockville manufacturer of substance detection and verification systems has been hit with a patent-infringement lawsuit by a competitor over a major product.
Cdex, which formed in 2001, began selling ValiMed last year to health care facilities such as the University of Maryland Medical Center, to help protect themselves against the growing trade of counterfeit medication, as well as guard against mistakes.
But officials with Analytical Spectral Devices of Boulder, Colo., alleged in a complaint filed in March in a Denver federal court that Cdex’s ValiMed is similar to the RxSpec system that Analytical patented in 2004, because ValiMed uses a ‘‘light source” to analyze and validate medication. Analytical officials seek unspecified damages and are asking the court to make Cdex stop selling ValiMed.
Brad Wills, a spokesman for Cdex, declined to comment. In the company’s latest quarterly report filed with the U.S. Securities and Exchange Commission last month, Cdex officials acknowledged the complaint.
‘‘As a matter of company policy, Cdex does not knowingly infringe upon the valid intellectual property or patent rights of other companies,” officials said. ‘‘Cdex will investigate [Analytical’s] complaint and take any and all necessary actions to remove [the] complaint against Cdex.”
The $39 billion counterfeit medication industry is expected to increase to $75 billion by 2010, according to the Center for Medicine in the Public Interest of New York. More hospitals and pharmacies are seeking better ways to guard against dispensing or selling phony medication, as well as making mistakes when administering prescribed drugs, and that’s where systems such as Cdex’s come in.
Counterfeits Rising
Fake prescription drugs worldwide account for about 11 percent of the total medication market. That is expected to increase to about 14 percent by 2010, according to the Center for Medicine in the Public Interest of New York.
Cdex officials knew about Analytical’s patent before selling ValiMed and signing an agreement with Baxa Corp. of Denver last year to distribute ValiMed, Analytical officials alleged in the lawsuit. The case has been referred to U.S. Magistrate Judge Craig Shaffer, and a hearing has been set for May 23.
Cdex recently received a notification of allowance from the U.S. Patent and Trademark Office for a product that will detect explosives or controlled substances. Officials expect that patent to be issued this spring; Cdex has four additional patents pending in the United States, plus more internationally.
Analytical, which was founded in 1990, has received seven patents related to verification of medication, including two for its RxSpec system, company officials said. Clients include the U.S. Department of Veteran Affairs mail-order pharmacies.
Cdex, which went public on the OTC bulletin board last year, reported that revenues for fiscal 2005, which ended in October, totaled $178,607, compared with $4,069 in 2004 and $191,964 in 2003. Revenue last year was from selling ValiMed, while sales in the previous two years derived from a U.S. Department of Defense contract to study the detection of chemical and biological agents using Cdex products.
Cdex reported a net loss of $5.2 million last fiscal year, which followed losses of $6 million and $4.1 million the two previous years. The company recently named a new CEO, James O. Griffin, who joined Cdex as COO last year. He succeeded Malcolm H. Philips, who is continuing as board chairman.
Besides its Rockville headquarters, Cdex has a research and development laboratory in Tucson, Ariz.
Analytical is privately held and has about $3 million in annual revenue, according to a recent report by credit bureau
Sort of OT: Cernium Introduces a Smarter Approach to Intelligent Video Analytics with Perceptrak(R) 4.0; New Release Expands Powerful 3-Series to Offer the Most Commercially Advanced Analytics Solution
ISC West 2006
RESTON, Va.--(BUSINESS WIRE)--April 4, 2006--Cernium Corporation, a pioneer in advanced video analytics and behavior recognition technologies, today announced a new release of its flagship intelligent video system, Perceptrak(R). The system is currently installed in more than 50 airports, commercial and government locations and cultural institutions throughout North America. Perceptrak version 4.0 expands the capabilities of Cernium's successful 3-series with new customer-driven features such as simplified setup and reconfiguration, expanded IP camera compatibility and "edge of the network" bandwidth management options. The result is a more flexible, robust and intuitive approach to video analytics.
"Perceptrak 4.0 combines the power of advanced video analytics with features and functions derived from experience in real-world security operations," said Phil Robertson, Cernium's Vice President for Corporate Development. "With major ease-of-use enhancements, plus several new customer-requested capabilities, such as multi-zone wrong-way motion and object-removal detection, Perceptrak will continue to lead the industry in providing a complete solution for video surveillance management."
Perceptrak 4.0 is driven by Cernium's patented Perception Based Analytics(TM) technology, which mimics the human vision process to offer the most efficient video analysis capability available. Perception Based Analytics enable Cernium customers to apply any combination of alerts simultaneously to as many as 16 distinct video sources using a single Pentium 4 processor. As a result, Perceptrak can support far greater numbers of video channels, with smaller space and bandwidth requirements, than competing systems that use conventional pixel analysis techniques.
Cernium introduced its first product, the best-selling ExitSentry(R), in 1996 and has the longest record of secure, reliable performance in the video analytics industry. Cernium's Perceptrak customers include Boeing, Johns Hopkins University, the City of Yonkers Municipal Parking Authority and George Washington's Mount Vernon Estate.
About Cernium
Cernium Corporation is the leading developer and provider of behavior recognition software and systems for the security industry, focusing on real-time video analysis. The company's advanced video security systems currently safeguard over one hundred facilities throughout North America, representing a range of industry sectors that include government, healthcare, transportation, hospitality, education and cultural institutions. Cernium's patented security products include Perceptrak(R) and ExitSentry(R). For more information visit www.cernium.com.
Contacts
Wills & Associates
Brad Wills, 301-767-1919
bwills@wills-pr.com
From: lmorovan 1/13/2006 8:33:09 AM
of 176
CDEX is in default with the SEC for failure to file the 4th quarter 10QSB report.
Public Reply | Prvt Reply | Mark
"It was your opinion" That was your statement. Don't look like an opinion to me. READ THE SEC FILINGS>>>
All reports have been filed on time.IMO You need some Medication, you have a big problem...On ignore again.
doyourdd, what other board are you talking about? Telling the truth about a company is helping shareholders and potential investors. I never said "Cdex is in default with the SEC for not filing on time", I said CDEX is in default with the SEC for filing the 4th quarter report, and that is the truth. I asked you to show me where did CDEX file the 4th quarter report and you never answered.
Now, there are several "untruths" you posted, and you know well that you are wrong. How does that bode with you claiming to be a Christian?
You are on another board, where they have tried to break into this technology.You have posted lies about cdex, mislead people, for what reason?You state your reason "to help shareholders" How is lying about a company helping shareholders.It was you that posted "Cdex is in default with the SEC for not filing on time" They were never late...
doyourdd, and your point is?
What's this: PALOMAR MEDICAL TECH Form 10K Filing Date 4-14-1998
Excerpts…
Wellman Laboratories ("Wellman Labs"), the world's largest biomedical laser research facility and part of the MGH Laser Center located in Boston, Massachusetts, was created to oversee and speed the flow of biomedical laser research from the laboratory to patient care. Funded in part by a grant from the Department of Energy, the MGH Laser Center brings together two strengths of MGH:
its clinical departments and the Wellman Labs. The MGH Laser Center works together with industry, academia and the Department of Energy Laboratories to access information and technology across a broad spectrum of laser and medical capabilities. The principals at Wellman Labs study the fundamental photophysical and photochemical properties and processes of biomolecules excited by ultraviolet, visible and near infrared radiation. Engineers, laser physicists and physicians familiar with all aspects of biomolecules, cells and tissue in vitro staff the labs. The scientists work side by side with the clinicians to understand the basic principles involved in the complex interactions of light and tissue. In 1994, the Company began a number of studies for the treatment of certain dermatological conditions using its diode laser at Wellman Labs. In 1995, those studies were expanded to include the Company's ruby lasers for cosmetic procedures. In 1997, those studies were again expanded to include the Company's diode lasers for cosmetic purposes. Wellman Labs and the Company are currently evaluating the data associated with these treatments. The Company works closely with Dr. R. Rox Anderson, the Research Director of the MGH Laser Center and Associate Professor of Dermatology at Harvard Medical School, who is a recognized expert in laser tissue interaction and the inventor of a number of laser procedures in use today. Dr. Anderson has authored over 60 papers in peer-reviewed publications relating to the use of lasers in dermatology, is the recipient of numerous awards in the field of laser medicine and serves as a member of the Blue Ribbon Government Liaison Committee of the American Society for Laser Medicine and Surgery. Dr. Anderson holds ten U.S. patents and has pending applications for an additional eleven. The Company feels that these types of relationships are critical in developing effective products for widespread use in the market on a timely basis, and that this method of conducting research and development provides a higher level of technical and clinical expertise than it could provide on its own and in a more cost-efficient manner.
PMP's Vice President of Research and Development, Gregory Altshuler, is the former Director of the Laser Center of the St. Petersburg (Russia) Institute of Fine Mechanics and Optics (the "St. Petersburg Laser Center)" and the Company continues to work closely with the St. Petersburg Laser Center, contracting out research and development tasks to them on a project basis. Palomar owns all inventions, developments and patents which result from the work performed at the St. Petersburg Laser Institute and funded by Palomar. In 1997, the Company spent approximately $100,000 on research and development conducted at the St. Petersburg Laser Institute. Dr. Altshuler holds approximately 50 patents in Russia in the field of lasers and the application of lasers in medicine, and has authored approximately 130 papers relating to laser physics, engineering and medicine.
While MGH focuses on the biological aspects of laser hair removal, Dr. Altshuler's in-house research and development team focuses on the physical aspects. Approximately 40 employees of the Company and its subsidiaries were engaged full time in research and development activities at December 31, 1997.
Pursuant to the Sales Agency, Development and License Agreement that the Company entered into with Coherent in November 1997, the Company has committed to spend the following amounts on research and development over the next three years: at least $5,000,000 in 1998, at least 10% of its 1998 gross revenues (minus commissions to Coherent) from cosmetic laser products ("Product Revenues") in 1999, and at least 10% of its 1999 Product Revenues in 2000.
= = = = = = =
BioProgress (BPRG) is interesting to me with Wellman Labs appearing in their SEC filings
BioProgress (BPRG) is interesting to me with Brunel University appearing
http://itprofessionalsurvival.com/content/view/1368/2/
Brunel University In-Cylinder Fuel and Species Measurements by Planar Laser Induced Fluorescence (PLIF)
http://dea.brunel.ac.uk/research/cerg/recent/plif.html
BioProgress (BPRG) is interesting to me, and it seems to be interesting to Raging Bull posters:
Lmorovan
stock_distributor
coquille
himanez
diddy
mike2999
Consider stock_distributor for example…
http://ragingbull.lycos.com/mboard/boards.cgi?board=BPRG&read=7344
Bioprogress Plc (BB: BPRG)
BPRG Quote | BPRG Msg Board | BPRG LiveCharts | BPRG Chart | BPRG News | BPRG Company Info | BPRG I-Watch | BPRG Insider | BPRG Analyst Recs | BPRG Top Holders
« BPRG Message list | Reply to msg. | Post new msg. « Older | Newer »
By: stock_distributor
29 Jan 2003, 03:01 PM EST
Msg. 7344 of 9882
Jump to msg. #
Does anyone know when we might expect to see the registration of the private unit holders shares???
Every month increases their holdings by 1/10th of the original placement. This dilution of the common holder should be halted via registration of their shares at the earliest practicable date before the 90% cap is hit.
Thank you.
t's this:
doyourdd, I am not involved with any competitor stock. Especially, since there is no competitor stock at this time.
Children's Hospitals and Clinics of Minnesota Selects CDEX ValiMed(TM) to Implement Medication Validation Solution; ValiMed System Verifies Compounded Medications and Doses, and Validates Narcotic Returns
ROCKVILLE, Md. & MINNEAPOLIS, Apr 03, 2006 (BUSINESS WIRE) CDEX, Inc. (CEXI) announced today that Children's Hospitals and Clinics of Minnesota has selected the ValiMed(TM) system to perform end-product testing of compounded intravenous medications in its pharmacy departments, and validation of returned narcotics in its operating room suites and nursing units. The ValiMed medication verification system, which was developed by CDEX ( www.cdex-inc.com) and is exclusively distributed by Baxa ( www.baxa.com), gives clinicians a quick, cost effective, and simple tool to further ensure medication safety by verifying medications are correctly compounded.
Children's of Minnesota is the eighth-largest children's health care organization in the U.S., with 319 staffed beds at its two hospital campuses in St. Paul and Minneapolis, Minnesota. An independent, not-for-profit health care system, Children's of Minnesota provides care through over 13,000 inpatient visits and more than 200,000 emergency room and other outpatient visits each year.
In a process that takes only seconds, ValiMed uses patent pending technology to validate compounded doses of high-risk medications prior to dispensing. The solution creates an added level of safety in the medication dispensing process, and is also used to validate narcotic returns as well as identify counterfeit medications.
"At Children's, our top priority is the safety of our patients. With the ValiMed product we will enhance our patient and medication safety by verifying compounded medication and narcotic returns right in the pharmacy," said Christine Koentopp, Director of Pharmacy at Children's Hospitals and Clinics of Minnesota.
"We are pleased that Children's of Minnesota has joined a list of nationally recognized healthcare organizations that have adopted this new health safety measure, and is the first healthcare system in Minnesota to use ValiMed," said Jim Griffin, CEO for CDEX. "It is gratifying to see ValiMed being accepted as a life safety and quality control product by healthcare professionals across the nation. The number of prestigious healthcare organizations that are adopting ValiMed to verify compounded medications and doses, and validate narcotic returns continues to grow."
The ValiMed solution uses light energy and a library of unique spectral fingerprints to validate drugs in solution. The device validates that the correct drugs in the correct amounts have been added to the dose during the compounding process. The ValiMed Medication Validation System is distributed under an exclusive agreement with Baxa Corporation ( www.baxa.com) of Englewood, Colorado.
About Children's Hospitals and Clinics of Minnesota
Children's of Minnesota has received national recognition for its work in patient safety, including a recent ranking as one of only eight pediatric hospitals among the "50 Exceptional U.S. Hospitals" by the Leapfrog Group, a consortium of 165 national employers that provide health coverage to 36 million employees. For more information about Children's of Minnesota, visit www.childrensmn.org.
About CDEX, Inc.
CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed is one line of CDEX products for the healthcare market. CDEX is headquartered in Rockville, Maryland with its research and development laboratory in Tucson, Arizona. For more information, visit www.cdex-inc.com and www.valimed.com.
Any statements made in this press release which contain information that is not historical are essentially forward-looking. Many forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks are detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.
SOURCE: CDEX, Inc.
L.Morovan, is your point on posting asd news, to warn investors or are you still involved in a competitor's stock?
Well lookie .. you....!! Just spreading your Glee all over these boards...lol
Analytical Spectral Devices, Inc. brings suit against CDEX, Inc.
Boulder, Colo., March 13, 2006 — Analytical Spectral Devices, Inc. (ASD), a manufacturer of rapid, precision, analytical and quality control instruments, announced today that it filed suit against CDEX, Inc. In its Complaint filed in the U.S. District Court in Denver, Colorado, ASD alleges that CDEX’s ValiMed Medical Validation System infringes upon ASD’s U.S. Patent No. 6,771,369. According to CEO and President, David Rzasa, “ASD filed this suit to protect its valuable intellectual property.”
The filing is a matter of public record. Click here to view the document.
About ASD
Founded in 1990, Analytical Spectral Devices manufactures cost-effective, precision, transportable and field-portable, laboratory-quality Vis/NIR spectrometers, spectroradiometers, spectrophotometers and corresponding software and accessories. ASD’s instruments perform well in a range of environmental conditions, in and outside the laboratory, and have applications in pharmaceutical, nutraceutical, analytical chemistry, mining, grain, food and dairy, remote sensing, pulp and paper industries world-wide. For more information, please contact Amanda Griffin, Analytical Spectral Devices, 5335 Sterling Dr., Suite A, Boulder, CO, 80301; 303/444-6522, 303/444-6825 (fax); www.asdi.com.
Contact: Amanda Griffin
Marketing Communications Manager
Analytical Spectral Devices
303.444.6522
mktg@asdi.com
We shall have to wait and see if anything comes of this..
I kinda think that we just may have a shot..
FY 2006 Port Security Grant (PSG) Program General Source: Department of Homeland Security
Reference Number: 97.056
Objectives: The PSG Program provides financial assistance for security enhancements. FY 2006 PSG GRANT GUIDANCE IS NOT AVAILABLE YET.
Expected May 2006.
Type of Assistance:
Grant Deadlines:
FY 2006 PSG GRANT GUIDANCE IS NOT AVAILABLE YET.
Expected May 2006.
You can go to the right and...."Log in as Guest"
http://www.rkb.mipt.org/contentdetail.cfm?content_id=119382
Print this page.
FY 2006 Port Security Grant (PSG) Program
General
--------------------------------------------------------------------------------
Source: Department of Homeland Security
Reference Number: 97.056
Objectives: The PSG Program provides financial assistance for security enhancements. FY 2006 PSG GRANT GUIDANCE IS NOT AVAILABLE YET. Expected May 2006.
Type of Assistance: Grant
Deadlines:
FY 2006 PSG GRANT GUIDANCE IS NOT AVAILABLE YET. Expected May 2006.
Eligibility:
Eligibility information forthcoming.
Description:
The PSG Program provides financial assistance on a competitive basis to owners and operators of ports, terminals, U.S. inspected passenger vessels and ferries, port authorities, and State and local agencies for physical security enhancements.
Grant Information Source:
Department of Homeland Security
810 Seventh Street, NW
Washington, DC 22015
202-205-9193
Website: http://www.ojp.usdoj.gov/odp/grants_programs.htm
(((If you link onto this you can go into the 2005 2006 port secutity grants..Eye Opener..ummmhmmm)))...
Additional Information
Office for Grants and Training Programs
Department of Homeland
******************
System and methods for detection and identification of chemical substances
*****************
[0031] The invention further provides a system and methods for facilitating the validation of medications and drugs within pharmacies, health care facilities, controlled substance disposal facilities as well as ***law enforcement facilities and customs facilities.***
[0021] The invention is also applicable in other situations.
For example, the system can provide a non-invasive means for directly measuring and identifying chemicals and drugs **(or containers suspected of containing such materials)** at ***ports of entry or during routines law enforcement activities.***
Similarly, the invention can be used a local pharmacies to verify the quality of prepared and individually formulated medications and is also applicable to home health care uses whereby the patient can validate their own medications prior to use.
http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FP...
Henry Ford News
Henry Ford Health System
Henry Ford Health System Announces $300 Million Investment Plan
Henry Ford Health System announced today that it plans to invest more than $300 million over the next five years in its flagship facility, Henry Ford Hospital.
“We are very pleased that Henry Ford Hospital is ranked among the top health care facilities in the United States,” says Nancy Schlichting, president and chief executive officer of Henry Ford Health System. “To maintain this leadership position, we are committed to updating our facility to meet the needs of 21st century patients.”
The investment, representing the single-largest investment in renovation and expansion in the hospital’s history, will be used for creating new patient rooms (80 private and 18 intensive beds), new operating suites, renovating research facilities and upgrading information technology.
“Reinvesting in Henry Ford Hospital will maintain and expand the flagship legacy that has been established through decades of providing the best medical services available to the citizens of Detroit and southeast Michigan and to patients from around the world,” says Anthony Armada, president and CEO of Henry Ford Hospital and Health Network.
Henry Ford Hospital, a 903-bed tertiary care hospital, education and research complex in Detroit’s New Center Area, opened its doors to patients in 1915. Since that time, it has grown to become one of the country’s most respected hospitals, attracting patients from nearly every state and numerous countries.
“Henry Ford Hospital will always remain the health system’s hub for research, education, transplant, trauma and other critical programs,” says Armada. Demand for services downtown has significantly increased in recent years and is anticipated to grow faster over the next decade. From 2003 to 2005, Henry Ford Hospital had the highest admission growth in Southeast Michigan, with an increase of 13.4 percent.
“All of this investment into the future and vision of Henry Ford Hospital translates into an economic engine for Detroit,” says Bob Riney, chief operating officer for Henry Ford Health System. “Not only for the jobs that will be created to help with the building and renovation but for the additional jobs necessary to maintain a larger, more vibrant medical campus.”
One major project is CarePlus Next Generation, a $40 million technology enhancement of Henry Ford’s electronic medical record. Unlike many health care environments in which the caregiver is unable to access information at the point of care, this next-generation system will place the data at the fingertips of the clinician through the deployment of one of the largest wireless networks in North America, covering 2.1 million square feet, and by providing caregivers with mobile devices such as pocket PCs, tablets and computers on wheels.
Other projects include:
Expansion of the Emergency Department - $10 million (2005 budget) A new lobby-waiting area, a sub-waiting area for patient’s family members and an additional 27 patient bays are being constructed. The expanded Emergency Room (ER) is scheduled to open in August (2006).
Expansion of the Henry Ford II Pavilion, the West Pavilion of the Main Hospital - $35 million Construction will begin in 2006 on a two-floor addition of the Henry Ford II Pavilion. The floors will house 80 new private patient rooms.
Increase Intensive Care Unit capacity - $28 million 18 intensive care beds will be added in the Henry Ford II Pavilion.
Expansion of existing Operating Rooms - $10 million Three additional operating rooms designed to accommodate new technology including robotics and additional pre- surgery and recovery room capacity are part of the expansion plans.
Initial clinic tower redevelopment - $18 million Several of the clinic floors of the 17 floor tower will undergo a major redesign and renovation. Design work is nearly finished for Oncology, Gastro and Nephrology/Transplant.
Research & education development - $13 million Over the next 10 years we anticipate that the investment will exceed $25 million. Several labs will be expanded and relocated.
Infrastructure - $50 million Non-clinical systems and equipment including emergency power upgrade.
Renovation and replacement - $100 million
Capitol investment dollars will be used to cover the costs of replacing and upgrading items like patient beds and equipment such as x-ray machines and blood monitors. “This investment in our hospital is also an investment in the city of Detroit and its future,” says Riney.
“We are committed to Detroit – the Ford name is indelibly linked with the city that has been our home now for more than 90 years. We will continue to provide the highest quality health care for city residents, for southeastern Michigan, and for the rest of the world in our second century of service.”
Just in the last year, Henry Ford opened:
The $8.2 million, 80,000-square-foot Henry Ford Medical Center in the beautiful, renovated space at New Center One; and
The $1.4 million Henry Ford Medical Center – Harbortown, on East Jefferson Avenue, in the Harbortown retail center in Detroit.
“We think it is phenomenal that Henry Ford would make such a significant investment in our city,” says Mayor Kwame M. Kilpatrick. “The message that they are sending with such an investment is consistent with that of the Next Detroit, where healthcare technology and research will play a major roll in creating the jobs of the future for Detroiters.”
Today, there are five Henry Ford medical centers in the city of Detroit and a total of 24 in southeast Michigan, including the 17-story outpatient medical clinic on this campus, all staffed by the 900-member Henry Ford Medical Group.
As a not-for-profit corporation, funding for the investments will come from re-investment of earnings from operations and philanthropic support.
Henry Ford Hospital Selects ValiMed From CDEX For Medication Validation
ValiMed Verifies Compounded Medications and Doses and Validates Narcotic Returns
ROCKVILLE, MD & DETROIT, MI– March 16, 2006 –Henry Ford Hospital has selected the ValiMed system to perform end-product testing of compounded intravenous medications in its pharmacy departments, and validation of returned narcotics in its operating room suites and nursing units. The ValiMed medication verification system was developed by CDEX (CEXI.OB) to give clinicians a quick, cost effective, and simple tool to further ensure medication safety by verifying medications are correctly compounded.
Henry Ford is a 903-bed tertiary care hospital, education and research complex in Detroit. The hospital is recognized for clinical excellence and innovations in the fields of cardiology and cardiovascular surgery, neurology and neurosurgery, orthopaedics and rehabilitation, organ transplantation, and treatment for prostate, breast and lung cancers, among others. Its Emergency Department is a Level 1 trauma center. Henry Ford is the flagship hospital for Henry Ford Health System, whose mission is to improve human life through excellence in the science and art of health care and healing.
In a process that takes only seconds, ValiMed uses patent-pending technology to validate compounded doses of high-risk medications prior to dispensing. The solution creates an added level of safety in the medication dispensing process, and is also used to validate narcotic returns as well as identify counterfeit medications.
"At Henry Ford, our top priority is patient safety. The ValiMed product strengthens our dispensing process by adding another level of safety to ensure compounded medications are accurately verified and narcotic returns are properly handled in the pharmacy," said Ed Szandzik, Director of Pharmacy at Henry Ford Hospital.
"We are pleased to be working with Henry Ford Hospital, yet another nationally recognized healthcare organization that has chosen to deploy ValiMed," said Jim Griffin, CEO for CDEX. “Partners like Henry Ford are valuable as CDEX continues its strategic growth in the healthcare sector.”
The ValiMed by CDEX solution uses light energy and a library of unique spectral fingerprints to validate drugs in solution. The device validates that the correct drugs in the correct amounts have been added to the dose during the compounding process.
About CDEX, Inc.
CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed is one line of CDEX products for the healthcare market. CDEX is headquartered in Rockville, Maryland with its research and development laboratory in Tucson, Arizona. For more information, visit www.cdex-inc.com.
Any statements made in this press release which contain information that is not historical are essentially forward-looking. Forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, the ability of the Company to raise capital to finance the development of its chemical detection products, the effectiveness, profitability and the marketability of those products, the ability of the Company to protect its proprietary information, the establishment of an efficient corporate operating structure as the Company grows and, other risks detailed from time-to-time in our filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statements.
Media Contact:
Brad Wills
Wills & Associates, Inc.
t. 301-767-1919
m. 301-346-7398
bwills@wills-pr.com
My post keep getting deleted by him:
« CEXI Message list | Reply to msg. | Post new msg. « Older | Newer »
By: capnmike
18 Jan 2006, 10:42 AM EST
Msg. 390 of 1442
Jump to msg. #
LMorovan-moderated board continues to experience DELETIONS. This eurekalert information reflects well on one of our CDEX client's
Public release date: 17-Jan-2006
The University of Utah Health Sciences Center is internationally regarded for its research and clinical expertise in the health sciences.
http://www.eurekalert.org/pub_releases/2006-01/uouh-urc011706.php
WHY would Lmorovan delete this??!!
= = = = = = =
OTC BB | Miscellaneous | Cdex, Inc. (CEXI) CEXI Quote/Level II - News - Quote - Chart
Public Reply | Private Reply | Keep Edit Msg (16 min left) | Previous | Next
Posted by: capnmike
In reply to: None Date:1/18/2006 10:37:02 AM
Post #of 6993
University of Utah Health Sciences Center is internationally regarded for its research and clinical expertise in the health sciences.
http://www.eurekalert.org/pub_releases/2006-01/uouh-urc011706.php
= = = = = = =
University of Utah Health Sciences Center
Addresses Narcotics Diversion
http://www.cdex-inc.com/pr/012605.html
http://www.cdex-inc.com/pr.html
= = = = = = =
Who are current users?
Dallas Children's Medical Center in Dallas, TX; UC-Davis Medical Center in Sacramento, CA; University of Utah Health System in Salt Lake City, UT; University of Michigan’s Mott Children’s Hospital in Ann Arbor, MI; Loyola University Medical Center in Chicago, IL; Maricopa Medical Center in Phoenix, AZ, and University of Maryland in Baltimore, MD.
http://www.baxa.com/OnlineHelp/ValiMed_FAQ.asp
= = = = = = =
UC-Davis Medical Center in Sacramento, CA
is also using our products....
UC DAVIS MEDICAL CENTER RANKS AMONG TOP HOSPITALS IN NATION FOR NURSING CARE
UC Davis Medical Center has been designated a Magnet Center of Nursing Excellence following a year-long review by the Washington-based American Nurses Credentialing Center (ANCC).
The medical center is one of only two in California, and one of only 39 health care organizations in the nation to receive this award. UC Davis first earned the prestigious recognition in April 1997 after a year-long, comprehensive evaluation by the ANCC. Hospitals receiving designation are required to maintain compliance during the four years that magnet status is effective.
http://www.ucdmc.ucdavis.edu/news/magnetnursing_center.html
= = = = = = =
National Cancer Institute awards additional
$14 million to UC Davis-LLNL Cancer Center
http://www.llnl.gov/pao/news/news_releases/2005/NR-05-08-03.html
= = = = = = =
October 2005
A leading healthcare survey has chosen 14 California hospitals, including the UC Davis Medical Center, for its Consumer Choice Award.
http://sacramento.bizjournals.com/sacramento/stories/2005/10/03/daily23.html
= = = = = = =
Loyola University Medical Center in Chicago, IL is using ValiMed products per the BAXA FAQ
Welcome to Loyola University Health System (LUHS), a private, academic health-care institution that is nationally recognized for its specialty care and research in such areas as cancer, cardiology and cardiovascular surgery, pediatrics, neonatology, neurosciences, burn and trauma care and organ transplantation.
http://www.luhs.org/index.cfm
Based in the western suburbs of Chicago, Loyola University Health System (LUHS) is a nationally recognized leader in providing specialty and primary health-care services and in conducting groundbreaking research in the treatment of heart disease, cancer, organ transplantation and neurological disorders.
http://www.luhs.org/about/index.htm
= = = = = = =
Medication error and quality related info here:
http://www.luhs.org/news/pubs/lmn/may04.pdf
= = = = = = =
National survey again names University of Chicago Hospitals to the Honor Roll of the best US hospitals
http://www.uchospitals.edu/about/awards/usnews.html
= = = = = = =
Integrated Advanced Information Management Systems (IAIMS) Awards, 1997 to Present
http://www.nlm.nih.gov/ep/AwardsIAIMS.html
Baxa to Feature ValiMed Medication Validation System at Interphex 2006
http://www.prweb.com/releases/2006/3/prweb360447.htm
Baxa Corporation features the innovative ValiMed System technology for rapid validation of high-risk medications at the Interphex 2006 trade show March 20-23, 2006, at Booth # C302. This new system provides the only effective means for preventing med errors, detecting narcotic abuse and ensuring the quality of batch compounds.
Englewood, Colo. March 20, 2006 – Baxa Corporation will feature its new ValiMed Medication Validation System at the upcoming Interphex meeting at the Jacob Javits Convention Center in New York City (http://interphex.com). Over the course of the three-day meeting, Baxa representatives will demonstrate how this unique technology prevents medication errors by validating drugs and concentrations, detecting counterfeit products for brand protection, and providing quality assurance for compounded products. The ValiMed System also is used for prevention and detection of narcotic diversion.
The ValiMed System provides clinicians a simple, cost-effective tool for ensuring medication safety. Its patent-pending technology identifies drug strength in real time, validating compounded doses of high-risk medications prior to dispensing. “The ValiMed Solution fits with Baxa Corporation's mission to improve pharmacy operations and increase the safety of admixture and administration activities,” notes Product Manager Mark Thrasher. “ValiMed complements our existing automation, admixture and drug delivery products well.”
According to the National Institute on Drug Abuse (NIDA), between 8% and 12% of healthcare workers have chemical dependencies. Healthcare professionals may be at increased risk of prescription drug abuse because of their easy access to medications, including controlled substances. Using the ValiMed Technology, pharmacy directors and other managers can detect narcotic loss and prevent on-the-job impairment, which can compromise patient care.
Pharmacists and other healthcare professionals continue to explore new uses for the medication validation offered by the ValiMed System. The system has applications for clinical trial validation and quality control, as well. The future of healthcare safety will be demonstrated at booth no. C302 during the Interphex exhibit hours.
For more than 30 years, Baxa Corporation has focused on developing systems and devices that streamline pharmacy operations, enhancing patient safety and improving efficiency. Under an agreement announced in early November, Baxa is the exclusive distributor of the CDEX ValiMed System for healthcare organizations in the United States and Canada.
About Baxa Corporation
Baxa, a customer-focused medical device company, provides innovative, solution-based technologies for fluid handling and delivery. Its systems and devices promote the safe and efficient preparation, handling, packaging, and administration of fluid medications. Privately held, Baxa Corporation has subsidiaries and sales offices in Canada and the United Kingdom; sales infrastructure in Belgium, Denmark, Finland, France, Germany, Luxembourg and the Netherlands; and distribution partners worldwide. Further information is available at http://www.baxa.com.
About CDEX, Inc.
CDEX Inc. (OTCBB: CEXI), is a technology development company focused on products using chemical detection and validation technologies. CDEX technology currently covers two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance. CDEX is headquartered in Rockville, Maryland, with a primary research and development laboratory in Tucson, Arizona. For more information, visit http://www.cdex-inc.com.
Additional information about the new ValiMed™ Medication Validation System and medication errors may be found at http://publicrelationsnewsroom.com/_wsn/page15.html.
Contacts:
Marian Robinson, Vice President, Marketing
Baxa Corporation http://www.baxa.com: 800.567.2292 ext. 2157 or 303.617.2157
Maggie Chamberlin Holben, APR
Absolutely Public Relations http://www.absolutelypr.com: 303.984.9801 or 303.669.3558
CDEX Announces Annual Shareholders Meeting
Last Update: 8:45 AM ET Mar 2, 2006
ROCKVILLE, Md., Mar 02, 2006 (BUSINESS WIRE) -- CDEX, Inc. (CEXI.OB), a developer of innovative technologies for detecting and validating chemical substances, announced today that its 2006 annual meeting of shareholders will be held on Friday, March 17, 2006, at 10:00 a.m. ET at the Doubletree Hotel, 1750 Rockville Pike, Rockville, MD, 20852 / telephone: 301-468-1100.
Proxy statements and proxy cards were mailed out on February 17, 2006. Proxies are to be returned to the address shown on the proxy card by no later than 11:59 p.m., March 16, 2006.
About CDEX, Inc.
CDEX, Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed is one line of CDEX products for the healthcare market. CDEX is headquartered in Rockville, Maryland with its research and development laboratory in Tucson, Arizona. For more information, visit www.cdex-inc.com and www.valimed.com.
Any statements made in this press release which contain information that is not historical are essentially forward-looking. Forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, the ability of the Company to raise capital to finance the development of its chemical detection products, the effectiveness, profitability and the marketability of those products, the ability of the Company to protect its proprietary information, the establishment of an efficient corporate operating structure as the Company grows and, other risks detailed from time-to-time in our filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statements.
SOURCE: CDEX, Inc.
For CDEX Brad Wills, 301-767-1919 bwills@wills-pr.com Copyright Business Wire 2006
CDEX Expands its Business to Include the Security Market
http://www.cdex-inc.com/pr/22706.html
CDEX, Inc. taps Charles C. Foster to serve as new Director of Business Development for Homeland Security
ROCKVILLE, MD – February 27, 2006 – CDEX, Inc. (CEXI.OB), a developer of innovative technologies for detecting and validating chemical substances, announced that Charles C. Foster has been appointed to the position of Director of Business Development, Homeland Security. Mr. Foster comes to CDEX from a background in law enforcement, sales and business development for security technologies.
At CDEX, Mr. Foster will be responsible for building the company’s sales channels by developing a network of strategic partners consisting of; prime government contractors and lead system integrators, and resellers for the company’s Homeland Security and commercial security business. The core technologies developed by CDEX for chemical substance detection and identification have numerous applications for law enforcement and defense, including illicit drug and explosive materials detection, as well as anti-counterfeiting solutions for brand safety and consumer protection.
“CDEX is very pleased to welcome Chuck Foster on board,” said Mr. James Griffin, President & CEO of CDEX, Inc. “His experience in public safety and security technologies will be invaluable to CDEX as it seeks to expands its business into the Homeland Security and commercial security sectors. Mr. Foster’s addition to the CDEX management team is an important step in the furtherance of our growth strategy for CDEX.”
Mr. Foster has had a nearly 30-year career in law enforcement, sales, and security technologies business development. Mr. Foster began his career as a police officer for New Castle County, Delaware, before entering the private sector in 1983 to pursue business development initiatives for a range of technology and security businesses, including, ADT, Controlled Access, Maris Equipment, and Infographic Systems. Prior to joining CDEX, Mr. Foster was Technical Relationship Manager for Cernium, Inc., the developer of intelligent video analytics systems. There he helped to establish the company’s market-leading position within video security, grow direct sales, and develop strategic relationships with integrators, VARs, and partnering businesses.
About CDEX, Inc.
CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed is one line of CDEX products for the healthcare market. CDEX is headquartered in Rockville, Maryland with its research and development laboratory in Tucson, Arizona. For more information, visit www.cdex-inc.com.
Any statements made in this press release which contain information that is not historical are essentially forward-looking. Forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, the ability of the Company to raise capital to finance the development of its chemical detection products, the effectiveness, profitability and the marketability of those products, the ability of the Company to protect its proprietary information, the establishment of an efficient corporate operating structure as the Company grows and, other risks detailed from time-to-time in our filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statements.
Media Contact:
Brad Wills
Wills & Associates, Inc.
t. 301-767-1919
m. 301-346-7398
bwills@wills-pr.com
Cdex targets $1B market for stopping fake drugs
http://www.bizjournals.com/washington/stories/2006/02/20/story4.html?from_rss=1Cdex
Neil Adler
Staff Reporter
Cdex, a Rockville business working on technology that detects chemicals, is about to go from developing a product to selling it. And that could mean big revenue and a larger staff for the small company seeking a piece of a $500 million to $1 billion market.
Recent Company News
» Baxa
» Maryland Pharmacists Association
» University of Maryland Medical Center
Latest News
» Fairfax County sees big increase in venture capital funding
» Private space flights given lift by Arlington company
» New economic development chief tapped in Anne Arundel
» New Maryland Web site helps startups seeking funds
» Tech firm GTSI names new CEO
More
» Companies in the News
» People in the News
» Get the latest business news on the go!
Brought to you by Cingular
With the first production run of its ValiMed system slated for April, Cdex expects to generate about $50 million in annual revenue in three years and $100 million by 2011.
The company (www.cdex-inc.com) has begun to sign up customers, including the University of Maryland Medical Center in Baltimore, for its chemical-detection system that helps medical professionals determine whether the drugs they receive are counterfeit.
"It's a big issue," says Howard Schiff, executive director of the Maryland Pharmacists Association. "Counterfeiting techniques are becoming more refined. It is very difficult to tell if [a drug] is counterfeit."
Cdex's technology uses X-rays and ultraviolet light -- as well as hardware and software -- to identify substances and weed out false positives, which happen frequently during attempts to detect hazardous materials. Customers are likely to pay about $25,000 for each ValiMed system.
"We're unaware of a competitor that is offering a similar product," says Jim Griffin, who joined Cdex Oct. 1 as chief operating officer and was named president and CEO Jan. 1. He replaced Malcolm Philips, who started the company in 2001.
"We believe what we have is exciting," says Griffin, who has also been named to Cdex's board.
The University of Maryland Medical Center will use ValiMed to perform end-product testing of intravenous medications in its pharmacy departments and to validate returned narcotics in operating rooms and nursing units. University officials say they are integrating the technology but preferred not to comment because they're just learning how to use the system.
The company has 17 employees between its Rockville headquarters and a facility for research and development in Tucson, Ariz. Griffin says he plans to at least double -- and perhaps triple -- the company's staff in the next 12 to 18 months. The new workers will be needed for sales, marketing and R&D.
Cdex, which is traded over the counter, plans to raise $3.5 million to $10 million this year for product development, although company executives won't say how the money will be secured. Cdex raised $3.6 million last year.
The company reported a net loss of
$5.2 million on revenue of $178,000 for fiscal 2005 ended Oct. 31, compared with a net loss of $5.9 million on revenue of roughly $4,000 a year earlier.
Cdex recently signed an agreement with Englewood, Colo.-based Baxa to sell its product line in the United States and Canada and is looking for partners to market the technology overseas.
The firm's technology targets health care but could be applied to the homeland security and brand protection markets, Griffin says. Defense officials, for example, could use it to screen for explosives and illegal drugs, and liquor industry leaders could use it to ensure the spirits they've ordered are legit.
Says Griffin: "Our opportunities are broad and vast."
E-mail: Nadler@bizjournals.com Phone: 703/816-0332
Cdex's profile page was changed.
CDEX Board of Directors
Dr. B. D. Liaw, Ph.D., Chairman of the Board, came to CDEX in October 2001 after a career in nuclear energy, having served for more than 20 years (1974-1995) at the U.S. Nuclear Regulatory Commission (NRC) and its predecessor agency, the Atomic Energy Commission. There Dr. Liaw, as the technical assistant to the NRC Chairman, played an important part of the technical rulemaking actions that followed the Three Mile Island Nuclear Plant accident, and helped set a new regulatory direction for the Commission that restored public confidence in nuclear energy in the United States. He has also been heavily involved in other critical rulemakings, such as that related to the high-level nuclear waste repository and low-level waste management. Dr. Liaw managed the NRC's regulatory oversight of the Tennessee Valley Authority’s (TVA) nuclear program, and was instrumental in bringing TVA's nuclear program back to full regulatory compliance. At the NRC, he was responsible for the engineering aspects of licensing reviews of the advanced reactor systems of the GE and Combustion Engineering designs, and the U.S. Navy's Seawolf nuclear submarine program. Dr. Liaw assisted in implementing nuclear safety regulatory programs in mainland China and Taiwan. He served as an advisor to the Taiwan Ministry of Economic Affairs, the Industrial Technology Research Institute, and The Taiwan Power Company (1995 to 2002). While in Taiwan, he also served as an Executive Member of the Board of Directors of the Taiwan Power Company, 1996-2001. Dr. Liaw holds a Ph.D. in Engineering Mechanics and an M.S. in Structural Engineering from Oklahoma State University, and an associate degree in Civil Engineering from the Taipei Institute of Technology.
Mr. George E. Dials, Director, joined the CDEX Board in July 2001. In February 2006, BWX Technologies named George Dials president and general manager of the National Nuclear Security Administration’s (NNSA) Y-12 National Security Complex in Oak Ridge, TN. Mr. Dials has spent nearly 30 years in the energy and nuclear industries, most recently serving as president and COO of a private hazardous waste disposal facility. Previously, he served as the president and general manager for TRW Environmental Safety Systems management and operations of the Yucca Mountain Project. His career has also included leadership positions with ICF Kaiser International, and the Department of Energy’s Carlsbad and Idaho Falls Offices. Mr. Dials entered the nuclear and energy industries after a ten-year career in the U.S. Army, where he served as an airborne ranger infantry officer in Germany, Vietnam, and Korea. Mr. Dials earned a Silver Star and Bronze Star for Valor in combat operations in Vietnam. As an Army nuclear weapons specialist, he was assigned to the Los Alamos National Laboratory for research on Army nuclear weapons planning and development. Mr. Dials holds an M.S. in nuclear engineering and an MS in political science from the Massachusetts Institute of Technology, and a B.S. in engineering from the United States Military Academy, West Point, New York.
Mr. Donald W. Strickland, Director, comes to CDEX from a 30-year career in successfully developing businesses internationally for both large public companies and technology startups. He has held executive positions at Eastman Kodak Company and Apple Computer, including heading product development, manufacturing, and sales. In 1996 he became CEO of PictureWorks Technology, a technology start up, which he sold for $200M in 2000 to IPIX Corporation, a public company traded on the NASDAQ exchange. Thereafter, he served as President and CEO of IPIX through 2004, during which time he led the company through a major restructuring, focusing on the security markets and taking the company to profitability. Mr. Strickland holds a bachelor's degree in physics from Virginia Tech, a master's degree in physics from the University of Notre Dame, a master's degree in optics from the University of Rochester, a master's degree in management from the Stanford University and a law degree from George Washington University.
Mr. James O. Griffin, President & CEO, Director and Secretary
(Biographical information included under CDEX Executive Management Team)
Mr. Timothy D. Shriver, Senior Vice President, Manufacturing Operations and Director (Biographical information included under CDEX Executive Management Team)
CDEX Executive Management Team
Mr. James O. Griffin, President & Chief Executive Officer, Director and Secretary, has served in senior executive positions in the high technology security and defense electronic systems industries for more than 25 years. Throughout his career, Mr. Griffin has focused on commercializing emerging technologies--growing sales and establishing productive distribution channels. Mr. Griffin joined CDEX in 2005, originally as chief operating officer, from a background in both public and private enterprises in the U.S., with extensive experience establishing and heading the international business units of several multinationals, including Sentech, Simplex, and Cardkey Systems. Immediately preceding CDEX, at Cernium, Inc., Mr. Griffin served as vice president of federal systems sales where he founded the company’s Washington, DC office, and opened relationships with government agencies for the developer of security video analytics systems. Previously, as vice president and general manager for the IPIX Corporation, he launched the company’s security division, IPIX Security, and established a customer base--that included the 2004 G-8 Summit--for the IPIX line of mission critical security imaging systems. As managing director of Simplex Asia Ltd., Mr. Griffin led a nearly two-year transformation of the fire alarm manufacturer’s Asian operations and reversed a major operating loss. Under Mr. Griffin’s leadership, the security services division of Mosler Inc. added contracts with the New York Port Authority to upgrade the security systems in the three airports serving New York City. For Cardkey Systems, Mr. Griffin created the company’s international division, linking together worldwide distributors to form cohesive sales channels. Mr. Griffin holds an MBA from Pepperdine University and a B.S. in Electrical Engineering from California State University.
Mr. Timothy D. Shriver, Senior Vice President, Manufacturing Operations and Director, is responsible for all CDEX manufacturing, quality assurance, and sustaining engineering. Mr. Shriver joined CDEX in 2001 from a career in nuclear power generation and the U.S. Navy. With an expertise in quality assurance and safety in power generation, Mr. Shriver served as an independent consultant to national and international nuclear utilities. Since 1981, he held positions in operations, quality assurance, regulatory compliance and auditing at nuclear power generation facilities including, Mississippi Power & Light, Arizona Palo Verde Nuclear Generating Station, Tennessee Valley Authority, and Ontario Power Generation. Mr. Shriver resigned his commission as a Lieutenant in the Navy in 1981 after 13 years of service. He holds a B.S. in Physics from Miami University in Oxford, Ohio.
Mr. Jerry Blair, Vice President, Sales and Marketing, is responsible for all sales and marketing within CDEX and for all business interfaces related to its products. Mr. Blair first came to CDEX in March 2004 to lead CDEX’s entrance into the medical market. Prior to joining CDEX, from 1988 to 1998, Mr. Blair held various roles within Cerner Corporation, a leading software supplier to the healthcare market. He was product manager for PharmNet, Cerner’s pharmacy solution, and business unit manager for all of Cerner’s pharmacy business. He also served as Clinical Marketing Manager. In 1998, he joined CareInsite, a Cerner investment that was eventually purchased by WebMD. He returned to Cerner in 2000 as Director, Medication Process Solutions where he remained until joining CDEX in 2004. Earlier in his career, Mr. Blair practiced hospital pharmacy and served as manager of professional services in the pharmaceutical industry. Mr. Blair holds a bachelor’s degree in Pharmacy from the University of Missouri at Kansas City, and an MBA in Executive Management at Rockhurst College.
Dr. Laurence J. Marsteller, Director of Research and Development, is a practicing M.D. with a background in physics, business management and investment banking. Dr. Marsteller has served as CDEX Director of R&D since 2005, and first joined the company in 2003. He maintains a limited private practice in family medicine, and has held leadership roles with healthcare providers, including the Ascension Health/Carondelet Health Network where he serves on the Medical Executive Committee and is Chair of the Department of Family Practice at Ascension Health/Carondelet St. Joseph’s Hospital. Dr. Marsteller has delivered testimony before the Food and Drug Administration Counterfeit Task Force to help develop programs for the FDA and other agencies to combat the problem of counterfeit pharmaceuticals and biologics. Before pursuing medicine, his interests and educational background led him to positions in investment banking with Morgan Stanley and Shearson Lehman, as well as a research position with the University of Arizona Lunar and Planetary Lab, Steward Observatory. Dr. Marsteller holds an M.D. from the University of Arizona College of Medicine, a M.Sc. in Astronomy from Yale University, and a B.Sc. in Physics from Georgetown University.
Mr. Shaun Priest, Director of Business Development, Healthcare, brings over 14 years of healthcare, technology, software management, sales, and marketing experience to CDEX. He is responsible for CDEX Healthcare, including sales, marketing, and development of strategic relationships. Prior to joining CDEX, Mr. Priest was vice president of sales and marketing at MedSeek, a developer of eHealth end-user portal solutions for patients, physicians, consumers, and employees, where he grew revenues threefold. He has also held leadership and sales positions with automated testing solutions developer Cyrano, and health information systems provider Cerner Corporation, where he was honored as salesman of the year in 1995 for Cerner’s Pharmacy product line. Mr. Priest began his career with Meditech, providing installation and support services for pharmacy information systems.
Dr. Wade M. Poteet, Ph.D., Principal Scientist, is a research physicist whose work has focused primarily on advanced instrumentation in optics, electro-optics and detector technologies. For CDEX, Dr. Poteet is responsible for research and development of remote species detection technologies and applications for new products. He joined CDEX in 2001 after a nearly 40 year career in this field with a range of public research institutions and private companies, including CP Systems, System Specialists, Infrared Laboratories, LTA, E/ERG, The University of Arizona, Rice University, and the National Radio Astronomy Observatory. His work has led to the development of products in the detection of explosives and illegal or counterfeit drugs, commercial infrared cameras, and an array of aerospace optical instrumentation. Dr. Poteet has published more than 45 referenced papers and 250 technical reports for the private sector and government agencies, and has been the recipient of NASA certificates of recognition and a public service group award in 1986 for his work on a Spacelab 2 research program. Dr. Poteet holds a Ph.D. in Experimental Solid State Physics, an M.S. in Physics, and a B.S. in Physics from the Virginia Polytechnic Institute.
So you are wondering what the Market Reform Movement is all about, what naked short selling is, what resources you should be scanning for a quick learn, and why you should care about any of it.
The Market Reform Movement is a loose affiliation of shareholder advocates, websites, attorneys, market pundits, shareholders and investors who are concerned about manipulative practices in the U.S. stock markets. The primary current focus is on Naked Short Selling/Failing to Deliver, which is a practice that many believe poses a systemic crisis to the market system.
To learn more about Naked Short Selling/Failing to Deliver, the following steps are probably advisable for anyone wishing to come up the learning curve quickly ...
http://www.thesanitycheck.com/GettingStarted/tabid/73/Default.aspx
Another New Press Release.....
http://www.cdex-inc.com/pr/21606b.html
PRESS RELEASE
BWX Technologies Names CDEX Director George Dials President and General Manager of the NNSA Y-12 National Security Complex in Oak Ridge, TN
ROCKVILLE, MD – FEBRUARY 16, 2006 – CDEX, Inc. (CEXI.OB) announces that Mr. George E. Dials, a CDEX Director since 2001, has been named President and General Manager of the National Nuclear Security Administration’s (NNSA) Y-12 National Security Complex in Oak Ridge, Tennessee operated by BWX Technologies (BWXT). Mr. Dials assumes responsibility effective February 20, 2006, and will continue his work with the CDEX Board.
In a February 6, news release, BWXT President and COO Mr. John A. Fees commented on the appointment: “George brings the experience necessary to manage and operate this nuclear weapons complex. For more than five years, BWXT has had a positive influence on Y-12’s operations. With George as part of our management team, it is a testament to our unyielding commitment to the Y-12 facility, employees and the DOE.”
Mr. Dials has spent nearly 30 years in the energy and nuclear industries, most recently serving as president and COO of a private hazardous waste disposal facility. Previously, he served as the president and general manager for TRW Environmental Safety Systems management and operations of the Yucca Mountain Project. His career has also included leadership positions with ICF Kaiser International, and the Department of Energy’s Carlsbad and Idaho Falls Offices. Mr. Dials entered the nuclear and energy industries after a ten-year career in the U.S. Army, where he served as an airborne ranger infantry officer in Germany, Vietnam, and Korea. Mr. Dials earned a Silver Star and Bronze Star for Valor in combat operations in Vietnam. As an Army nuclear weapons specialist, he was assigned to the Los Alamos National Laboratory for research on Army nuclear weapons planning and development. Mr. Dials holds an M.S. in nuclear engineering and an M.S. in political science from the Massachusetts Institute of Technology, and a B.S. in engineering from the United States Military Academy, West Point, New York.
BWXT, headquartered in Lynchburg, VA, has a long history in nuclear manufacturing and operations, both in the DOE and at its unique, highly secure, privately owned and operated nuclear manufacturing and laboratory facilities. Supplying the U.S. government and commercial clients with nuclear products and services for over 50 years, BWXT has unparalleled experience in nuclear safeguards and security. BWXT is responsible for the operations of the DOE’s National Nuclear Security Administration’s Pantex Plant in Texas and Y-12 National Security Complex in Tennessee, along with nuclear operations at the Idaho National Laboratory. BWXT has more than 11,300 employees in 11 states and is a subsidiary of McDermott International, Inc. (NYSE: MDR).
About CDEX, Inc.
CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed is one line of CDEX products for the healthcare market. CDEX is headquartered in Rockville, Maryland with its research and development laboratory in Tucson, Arizona. For more information, visit
www.cdex-inc.com.
Any statements made in this press release which contain information that is not historical are essentially forward-looking. Forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, the ability of the Company to raise capital to finance the development of its chemical detection products, the effectiveness, profitability and the marketability of those products, the ability of the Company to protect its proprietary information, the establishment of an efficient corporate operating structure as the Company grows and, other risks detailed from time-to-time in our filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statements.
CDEX Enhances Protection of Intellectual Property Around Substance Detection and Validation Technologies
Thursday February 16, 4:15 pm ET
ROCKVILLE, Md.--(BUSINESS WIRE)--Feb. 16, 2006--CDEX, Inc. (OTCBB:CEXI.OB - News), a developer of innovative technologies for detecting and validating chemical substances, received a notification of allowance from the U.S. Patent and Trademark Office for Patent Application Publication Number 20030128804, entitled "System and Method for Adapting a Software Control in an Operating Environment." The patent applies to a system and method developed by CDEX for detecting substances--such as explosives or controlled substances. The technology exposes target substances to an x-ray energy beam and then analyzes and compares the released fluorescent energy to a database of unique energy signatures of known substances. CDEX anticipates issuance of the patent in the spring of 2006.
ADVERTISEMENT
"Protection of our intellectual property is a key part of our ongoing plan for growth," said Jim Griffin, president and CEO of CDEX. "We are pleased that the US Patent office has recognized the uniqueness of our technology."
All current CDEX products, such as the ValiMed(TM) medication validation unit used by hospitals throughout the U.S., are based on applying the same underlying photoelectric technology for which the company has, in addition to this recently announced patent, four additional patents pending. CDEX has also filed corresponding international applications for each of these.
The CDEX ValiMed System offers clinicians a simple and cost-effective tool to ensure medication safety by verifying that medications are correctly compounded. The ValiMed System also validates narcotic returns. ValiMed is sold through the Baxa Corporation, which serves as the exclusive distributor in the United States and Canada of ValiMed Impaired Clinician Solution, ValiMed Regulatory Compliance Solution, and ValiMed Patient Safety Solution.
CDEX core technologies are highly scalable. The company is currently developing products that incorporate the same patent pending technologies currently employed in existing CDEX products for other market segments, including:
1. Security and Public Safety - Identification of substances of
concern (e.g., explosives, illegal drugs, chemical/biological
weapons, and the detection of counterfeit drugs and medications to
assist in the protection of the nation's pharmaceuticals supply);
and
2. Healthcare - Validation of substances and quality assurance
(e.g., validation of prescription and compounded medications to
provide for patient safety, detection of the diversion of
narcotics and controlled substances returned from operating room
suites to the operating room pharmacy, and detection of
counterfeit drugs and medications); and
3. Brand Protection - Detection of counterfeit or sub-par products
for brand protection (i.e., quality assurance inspection of
incoming raw materials, outgoing final products, and products in
the distribution channel).
About CDEX, Inc.
CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed is one line of CDEX products for the healthcare market. CDEX is headquartered in Rockville, Maryland with its research and development laboratory in Tucson, Arizona. For more information, visit www.cdex-inc.com and www.valimed.com.
Any statements made in this press release, which contain information that is not historical, are essentially forward-looking. Many forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks are detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.
Viking that was funny, but here is a funnier one
Posted by: lmorovan
In reply to: ontheedge01 who wrote msg# 8552 Date:2/15/2006 9:15:01 AM
Post #of 8595
ontheedge01, I was part of the gang too at one time when I was still blinded by yours and a few others fairy tales. Crow is right and truthful. I could bring up specific messages to support the claim, but will not convert this board into a joke. If you want to discuss the issue any further, I advise you to do it on another forum. As a matter of fact, you can create your own board even here on iHub.
Imagine 6 or 7 non-shareholders and one holier than thou.
Kinda makes him a little late and a dollar short
Lighten up and enjoy a good joke.
Three ducks walk into a bar.
> >>"Say, what's your name?" the bartender asked the first duck.
> >>"Huey," was the reply.
> >>"How's your day been, Huey?"
> >>
> >>"Great. Lovely day. Had a ball. Been in and out of puddles all day.
> >>What else could a duck want?" said Huey.
> >>
> >>"Oh. That's nice," said the bartender. He turned to the second duck,
> >>"Hi, and what's your name?"
> >>
> >>"Dewey," came the answer from duck number two.
> >>
> >>"So how's your day been, Dewey!?" he asked.
> >>"Great. Lovely day. I've had a ball too. Been in and out of puddles
> >>all day myself. What else could a duck want?"
> >>
> >>The bartender turned to the third duck and said, "So, you must be Louie?"
> >>
> >>"No," she said, batting her eyelashes.
> >> "My name is Puddles."
Viking: Read the PR closer and then realize why BAXA stated that there will be at least 90 day turnaround on delivery.
It is obvious that ValiMed has finally had any bugs worked out and CDEX is ready to turn the production of ValiMed over to a company that seems to be well qualified to take it home.
An earlier report stated that they have reduced the size and revised the capabilities of holding the new CDEX required container(forget what it is called,?cup?)These modifications normally would require a revised (or new)plastic injection mold,hence the new machining and injection molding contractors.Maybe it is no longer a 2 foot shoe box as it was described. this is the result of testing.Remember they were using off the shelf equipment for the prototypes. Smart Move IMO.
I don't expect to see any units until late March or early April. Of course I don't know that for sure, but from what I can read and reason out,that is my timetable.
As for the delay,why would you want to have a premature news release. Is it not possible that one of the five or so new suppliers hadn't really checked in for sure,on the 3rd of Feb.
You seem to want to revert to the LH line of bull,(Say it and keep your fingers crossed).
Perhaps Brad Wills and co will not issue reports until everything is locked up. Notice also that it was not put on the news wires,telling me that CDEX didn't want the price to run yet. It is one thing to tell people who are watching the web site , and another to let the investing world know that CDEX is getting ready to run.Perhaps it was a planned opportunity allowing long suffering investors to get a jump on the market. I know I took advantage of it. Hopefully it will pay off.
Could you have done anything the 3 rd of Feb that you could not have done yesterday? The only one that should take advantage of that situation is lemonhead,he made a big deal of it. Sounds like he got to you,LOL.
I concur with raiderman,this will be our year, but why rush it,without being aware of the problems.
Trust has carried us this far(further than we should have realistically imagined three years ago). IMO let it play out,and we will all be happier for it. How much happier remains a question.IMO
IMO Look for Strickland to move up into management,in the near future.Again,IMO an "Outside" board of director's position may just be wasting his knowledge and abilities,depending on what he is working at presently, plus they may have to have a BAXA man on the board.
Great news Sassy, but why is this coming out 7 days after the fact? The units will be rolling off an assembly line. That is a really great news. I am happy, but pissed off at the way we had to wait for the news.
CDEX Manufacturing Contract NEWS
http://www.cdex-inc.com/pr/20306.html
Mastek-InnerStep, Inc. Secures Manufacturing Contract With CDEX, Inc.
- BusinessLinc Program Key to Success -
TUCSON, AZ (February 3, 2006) – CDEX, Inc. (CEXI.OB), a public technology development company based in Rockville, Maryland, has selected Mastek-InnerStep, Inc. of Tucson, a high-technology supplier of electro-mechanical assembly and engineering, to serve as the contract manufacturer for its ValiMed™ devices. The ValiMed™ system is used for medication validation by hospital pharmacists to verify that patients are receiving the correct compounded medications in the correct dosages.
Through CDEX’s contract arrangement, Mastek-InnerStep will provide turnkey production services, including manufacturing engineering, project management, pre-production manufacturing, and electronic assembly.
“In terms of employment, we are up about 20% over the past year, and we expect to grow by about another 20 to 25% in the next year,” said Dave Duncan in Business Development at Mastek-InnerStep. “We have 36 employees, and are now looking to add 8 to 10 over the next year. This is a big win for us.”
“In bidding this project, our first call was to the BusinessLINC Program at Tucson Regional Economic Opportunities, Inc. (TREO) in order to secure specialty vendors for specific applications. BusinessLINC provided several local vendors for each application and we chose qualified vendors to be part of the New Product Introduction (NPI) team.”
Selected for this project were The Metal Man for laser sheet metal fabrication and forming, Anderson Painting for technical powder coating, Schnipke Southwest for plastic injection molding, and Whitmark Packaging for shipping carton design, and TAG Engineering for machining.
"We're thrilled to have our contract manufacturing based in Tucson. One of the key advantages is having a resource like BusinessLinc to identify vendor capabilities for further expansion. This gives us production capacity for our ValiMed product line and fulfills a critical milestone in the implementation of our growth strategy, " said Jim Griffin, CEO of CDEX.
About TREO
Tucson’s newest regional economic development entity was created to provide insight, infrastructure, resources and development efforts that will ensure ongoing economic prosperity throughout the Southern Arizona region. TREO’s programs support a regional economic development environment that allows all businesses (micro, small and large) to grow and thrive. For more information, visit www.treoaz.org
About CDEX, Inc.
CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed is one line of CDEX products for the healthcare market. CDEX is headquartered in Rockville, Maryland with its research and development laboratory in Tucson, Arizona. For more information, visit www.cdex-inc.com.
About Mastek-InnerStep
Mastek-InnerStep is a locally owned contract manufacturer in Tucson. With core capabilities in electronics assembly, Mastek provides a range of services from printed circuit board assembly to complete fulfillment, shipping completed, tested and warranted, products to the end user. Mastek customers comprise diverse industry segments including audio-visual, laboratory, testing & analysis equipment, medical instrumentation and military/aerospace projects. For more information, visit www.innerstep.com
Any statements made in this press release which contain information that is not historical are essentially forward-looking. Forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, the ability of the Company to raise capital to finance the development of its chemical detection products, the effectiveness, profitability and the marketability of those products, the ability of the Company to protect its proprietary information, the establishment of an efficient corporate operating structure as the Company grows and, other risks detailed from time-to-time in our filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statements.
CDEX Appoints New Directors; CDEX Board of Directors Accepts Resignation of Two Directors, Appoints Two New Directors; Former Chairman of the Board of Directors Steps Down
ROCKVILLE, Md., Feb 06, 2006 (BUSINESS WIRE) -- CDEX, Inc. (OTCBB: CEXI), a
public technology development company based in Rockville, Maryland, today
announces that Mr. Malcolm Philips, Chairman of the Board of Directors, and Mr.
John Knubel, Director, have submitted their resignations to the Board of
Directors, effective February 3, 2006. The Board of Directors has accepted their
resignations and has appointed James O. Griffin, President and CEO of CDEX,
Inc., as an inside Director and Donald W. Strickland, an outside Director, to
fill these two vacancies, and serve on the Board until such time as they stand
for election at the company's annual shareholder's meeting on March 17, 2006.
Dr. B. D. Liaw was elected by the Board to succeed Mr. Philips as Chairman of
the Board of Directors.
"As Founder, President and CEO, and Chairman of the Board of CDEX, Mr. Philips
provided guidance to the company during its difficult start up phase and was a
consistent and steadying influence for the company during its transition to a
public company. Malcolm leaves behind a strong management team, a strong Board
of Directors, and a company poised for growth, all of which are the results of
planned succession that he has been implementing during the past year," said Dr.
Liaw. "The Board of Directors thanks Mr. Malcolm Philips for his untiring
leadership and unwavering commitment to CDEX over the past four years. As we
salute Malcolm and bid him farewell, we wish him success in his pursuits of
other interests, and we wish he and his family nothing but the very best in the
future."
"The Board also expresses its thanks for the service provided to it by Mr. John
Knubel, who served as the chairman of our financial committee and was our
Sarbanes-Oxley compliance consultant," said Dr. Liaw.
"It is my pleasure to welcome Mr. Donald W. Strickland and Mr. James O. Griffin
to our Board of Directors. Don brings a wealth of public company knowledge to
our Board and we welcome his insights and experience," added Dr. Liaw.
Mr. Strickland will serve as the chairman of the financial committee, replacing
Mr. Knubel. Mr. Griffin will serve as Secretary of the Board, and a member of
the financial committee.
About Donald W. Strickland
Mr. Donald W. Strickland, Director, comes to CDEX from a 30-year career in
successfully developing businesses internationally for both large public
companies and technology startups. He has held executive positions at Eastman
Kodak Company and Apple Computer, including heading product development,
manufacturing, and sales. In 1996 he became CEO of PictureWorks Technology, a
technology start up, which he sold for $200M in 2000 to IPIX Corporation, a
public company traded on the Nasdaq exchange. Thereafter, he served as President
and CEO of IPIX through 2004, during which time he led the company through a
major restructuring, focusing on the security markets and taking the company to
profitability. Mr. Strickland holds a bachelor's degree in physics from Virginia
Tech, a master's degree in physics from the University of Notre Dame, a master's
degree in optics from the University of Rochester, a master's degree in
management from the Stanford University and a law degree from George Washington
University.
About James O. Griffin
Mr. James O. Griffin, President & Chief Executive Officer, has served in senior
executive positions in the high technology security and defense electronic
systems industries for more than 25 years. Throughout his career, Mr. Griffin
has focused on commercializing emerging technologies--growing sales and
establishing productive distribution channels. Mr. Griffin joined CDEX in 2005,
originally as chief operating officer, from a background in both public and
private enterprises in the U.S., with extensive experience establishing and
heading the international business units of several multinationals, including
Sentech, Simplex, and Cardkey Systems. Immediately preceding CDEX, at Cernium,
Inc., Mr. Griffin served as vice president of federal systems sales where he
founded the company's Washington, DC office, and opened relationships with
government agencies for the developer of security video analytics systems.
Previously, as vice president and general manager for the IPIX Corporation, he
launched the company's security division, IPIX Security, and established a
customer base that included the 2004 G-8 Summit for the IPIX line of mission
critical security imaging systems. As managing director of Simplex Asia Ltd.,
Mr. Griffin led a nearly two-year transformation of the fire alarm
manufacturer's Asian operations and reversed a major operating loss. Under Mr.
Griffin's leadership, the security services division of Mosler Inc. added
contracts with the New York Port Authority to upgrade the security systems in
the three airports serving New York City. For Cardkey Systems, Mr. Griffin
created the company's international division, linking together worldwide
distributors to form cohesive sales channels. Mr. Griffin holds an MBA from
Pepperdine University and a B.S. in Electrical Engineering from California State
University.
About CDEX, Inc.
CDEX Inc. is a technology development company with a current focus on developing
and marketing products using chemical detection and validation technologies. At
present, CDEX is devoting its resources to two distinct areas: (i)
identification of substances of concern (e.g., explosives and illegal drugs for
homeland security); and (ii) validation of substances for anti-counterfeiting,
brand protection and quality assurance (e.g., validation of prescription
medication and detection of counterfeit or sub-par products for brand
protection). ValiMed is one line of CDEX products for the healthcare market.
CDEX is headquartered in Rockville, Maryland with its research and development
laboratory in Tucson, Arizona. For more information, visit www.cdex-inc.com.
Any statements made in this press release, which contain information that is not
historical, are essentially forward-looking. Many forward-looking statements can
be identified by the use of words such as "expects," "plans," "may,"
"anticipates," "believes," "should," "intends," "estimates," and other words of
similar meaning. These statements are subject to risks and uncertainties that
cannot be predicted or quantified and, consequently, actual results may differ
materially from those expressed or implied by such forward-looking statements.
Such risks are detailed from time-to-time in filings with the Securities and
Exchange Commission. There is no obligation to publicly update any
forward-looking statements.
SOURCE: CDEX, Inc.
Quarterly Filed here is the link!
http://www.sec.gov/Archives/edgar/data/1173738/000121465906000130/0001214659-06-000130.txt
All the CDEX Press releases..
http://www.cdex-inc.com/pr.html
PRESS RELEASES
• Mount Carmel West Hospital Partners with CDEX to Implement ValiMed Medication Validation Solution Jan. 11, 2006
• CDEX, Inc. Appoints James O. Griffin as Chief Executive Officer Jan. 3, 2006
• University of Maryland Medical Center Partners with CDEX to Implement Medication Validation Solution Nov. 29, 2005
• CDEX to Demonstrate Validation of Flu Vaccine and Flu Medications at The American Society of Health Systems Pharmacists (ASHP) MidYear Clinical Meeting December 4-8 Nov. 14, 2005
•CDEX and Baxa Sign Distribution Agreement Nov. 10, 2005
•BAXA and CDEX Announce Strategic Alignment Nov. 2, 2005
•CDEX’s ValiMed Unit Selected to Validate Controlled Substance Returns Oct. 13, 2005
•Maricopa Medical Center Selects CDEX’s ValiMed Technology for End Product Testing Oct. 12, 2005
•CDEX Announces Implementation and Acceptance of its ValiMed Patient Safety Solution Sept. 29, 2005
•CDEX Announces New Chief Operations Officer Sept. 19, 2005
•CDEX Begins Trading on OTCBB April 14, 2005
•University of Utah Health Sciences Center Addresses Narcotics Diversion Jan. 26, 2005
•CDEX Announces Dallas Children's Medical Center Acceptance of ValiMed Impaired Clinician Solution Jan. 14, 2005
•CDEX Announces New Vice President of Business Operations Jan. 3, 2005
•CDEX Announces Land Mine Contract with US Army June 3, 2002
•CDEX Announces Independent Verification Testing of Explosive Detection Technology May 21, 2002
•CDEX-Inc. Issues Test Reports on the EM-1 Sept. 5, 2001
Like the Bo-weevil in the old song by tex Ritter,,, "Lookin fer a home"..
'pears lak the RB boards are late lamented..or NOT lamented..depending on ones pointaview..
Olly-olly-in-free!
Where have all the posters from RB gone? I thought they'd be here, cuz I knew you wouldn't go to the loony board.
I looked for boards on Yahoo and SI but didn't find any.
Thanks, Charlie
OT: A Mouse Story:
> A mouse looked through the crack in the wall to see the farmer and his
>wife open a package. "What food might this contain?" The mouse wondered -
>he was devastated to discover it was a mousetrap. Retreating to the
>farmyard, the mouse proclaimed the warning. "There is a mousetrap in the
>house! There is a mousetrap in the house!" The chicken clucked and
>scratched, raised her head and said, "Mr. Mouse, I can tell this is a grave
>concern to you, but it is of no consequence to me. I cannot be bothered by
>it." The mouse turned to the pig and told him, "There is a mousetrap in
>the house! There is a mousetrap in the house!" The pig sympathized, but
>said, "I am so very sorry, Mr. Mouse, but there is nothing I can do about
>it but pray. Be assured you are in my prayers." The mouse turned to the
>cow and said "There is a mousetrap in the house! There is a mousetrap in
>the house!" The cow said, "Wow, Mr. Mouse. I'm sorry for you, but it's no
>skin off my nose." So, the mouse returned to the house, head down and
>dejected, to face the farmer's mousetrap alone. That very night a sound
>was heard throughout the house -- like the sound of a mousetrap catching
>its prey. The farmer's wife rushed to see what was caught. In the
>darkness, she did not see it was a venomous snake whose tail the trap had
>caught. The snake bit the farmer's wife. The farmer rushed her to the
>hospital, and she returned home with a fever. Everyone knows you treat a
>fever with fresh chicken soup, so the farmer took his hatchet to the
>farmyard for the soup's main ingredient. But his wife's sickness
>continued, so friends and neighbors came to sit with her around the clock.
>To feed them, the farmer butchered the pig. The farmer's wife did not get
>well; she died. So many people came for her funeral, the farmer had the cow
>slaughtered to provide enough meat for all of them. The mouse looked upon
>it all from his crack in the wall with great sadness. So, the next time
>you hear someone is facing a problem and think it doesn't concern you,
>remember -- when one of us is threatened, we are all at risk. We are all
>involved in this journey called life. We must keep an eye out for one
>another and make an extra effort to encourage one another.
New Press Release
Press Release Source: CDEX, Inc.
Mount Carmel West Hospital Partners with CDEX to Implement ValiMed Medication Validation Solution
Wednesday January 11, 1:45 pm ET
CDEX ValiMed System Chosen by Mount Carmel West to Verify Compounded Medications and Doses, Validate Narcotic Returns, and Screen for Counterfeit Pharmaceuticals
ROCKVILLE, Md. & COLUMBUS, Ohio--(BUSINESS WIRE)--Jan. 11, 2006--Mount Carmel West Hospital has selected the CDEX (OTCBB:CEXI - News) ValiMed system to perform end-product testing of compounded intravenous medications in its pharmacy departments, and validation of returned narcotics in its operating room suites and nursing units. The CDEX ValiMed medication verification system was developed to give clinicians a quick, cost effective, and simple tool to further ensure medication safety by verifying medications are correctly compounded.
ADVERTISEMENT
In a process that takes only seconds, ValiMed uses patent pending technology to validate compounded doses of high-risk medications prior to dispensing. The solution creates an added level of safety in the medication dispensing process, and is also used to validate narcotic returns as well as screen for counterfeit medications.
"Medication safety is our top priority at Mount Carmel and ValiMed enhances the safeguard procedures we currently have in place without adding additional resources. The ValiMed product offers us the opportunity to validate end-products being dispensed from the pharmacy and to validate returned narcotics," said Joe Melucci, Director of Pharmacy at Mount Carmel West.
"CDEX is very excited to be working with Mount Carmel to extend our new validation technology to a community hospital setting," said Jim Griffin, CEO of CDEX.
The CDEX ValiMed solution utilizes a discrete energy source to produce unique return photon signatures, which are referenced against a database of unique medication spectral fingerprints to validate pharmaceuticals. The device validates that the correct medications in the correct amounts have been added to the dose during the compounding process.
About Mount Carmel West
With a history of serving the community since 1886, Mount Carmel offers a broad range of healthcare services in the central Ohio region and treats more than a half million patients each year. The healthcare system includes three hospitals - Mount Carmel East, Mount Carmel West, and Mount Carmel St. Ann's; outpatient services; home care; hospice care; home medical equipment services; an ambulance and mobile intensive care service; a community outreach program for the poor and under-served; a college of nursing; and a Medicare HMO. Mount Carmel is a member of Trinity Health, based in Novi, Michigan. For more information about Mount Carmel, visit the healthcare system's Website at www.mountcarmelhealth.com
About CDEX, Inc.
CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed is one line of CDEX products for the healthcare market. CDEX is headquartered in Rockville, Maryland with its research and development laboratory in Tucson, Arizona. For more information, visit www.cdex-inc.com and www.valimed.com.
Any statements made in this press release, which contain information that is not historical, are essentially forward-looking. Many forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks are detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.
Contact:
CDEX, Inc.
Media Contact:
Brad Wills, 301-767-1919
bwills@wills-pr.com
Business Description Cdex Inc.. The Company's principal activities are to develop and market products using chemical detection and validation technologies. The Company is into the development of products for two distinct markets: identification of substances of concern such as explosives, illegal drugs and chemical/biological weapons; and validation of substances for anti-counterfeiting, brand protection and quality assurance such as validation of prescription medication; detection of counterfeit or sub-par products for brand protection; and quality assurance inspection of incoming raw materials and outgoing final products. The Company operates in the United States.
Followers
|
19
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
516
|
Created
|
05/17/04
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |